Skip to main content
. 2023 Sep 25;85(6):650–658. doi: 10.1055/s-0043-1774792

Table 2. Induction chemotherapy in patients with sinonasal malignancies with brain invasion and neurological deficits (5-FU: - 5-fluorouracil; IC: induction chemotherapy).

Induction cohort with brain invasion Induction cohort with neurological deficits
Induction chemotherapy agents
 Platinum +  t axane 6 (15%) 4 (12.9%)
 Platinum + 5-FU 1 (2.5%) 3 (9.7%)
 Platinum +  t axane + 5-FU 3 (7.5%) 2 (6.5%)
 Platinum +  t axane + ifosfamide 3 (7.5%) 4 (12.9%)
 Platinum +  e toposide 23 (57.5%) 15 (48.4%)
 Platinum +  e toposide + ifosfamide 1 (2.5%) 1 (3.2%)
 Platinum +  e toposide + vincristine 1 (2.5%)
 Adriamycin + ifosfamide + vincristine 1 (2.5%)
 Irinotecan 1 (2.5%)
 Platinum +  t axane + cetuximab 1 (3.2%)
 Platinum +  t axane + gemcitabine 1 (3.2%)
Cycles of IC Avg: 3.2 (SD: 1.4), median: 3 Avg: 3.1 (SD: 0.9), median: 3
Radiographic response to induction chemotherapy
 Complete r esponse 5 (12.5%) 3 (9.7%)
 Partial r esponse 27 (67.5%) 19 (61.3%)
 Stable d isease 7 (17.5%) 6 (19.4%)
 Disease p rogression 1 (2.5%) 3 (9.7%)
Interruption in i nduction c hemotherapy 5 (12.5%) 2 (6.5%)
Adverse events to systemic therapy
 Hematologic 9 (22.5%) 4 (12.9%)
 Nonhematologic 12 (30%) 7 (22.6%)

Abbreviation: SD, standard deviation.